A pale yellow tablet with a cross breakline on one side. The tablets can be divided into halves or quarters.

Praziquantel 50mg

Pyrantel 50mg (equivalent to 144mg pyrantel embonate)

Febantel 150mg

For the treatment of mixed infections with the following gastrointestinal tapeworms and roundworms in dogs and puppies

Ascarids: Toxocara canis, Toxascaris leonina (adult and late immature forms).

Hookworms: Uncinaria stenocephala, Ancylostoma caninum (adults).

Whipworms: Trichuris vulpis (adults).

Tapeworms (cestodes): Echinococcus species, (E. granulosus, E. multilocularis), Taenia species (T. hydatigena, T. pisiformis, T. taeniformis), Dipylidium caninum (adult and immature forms).

Single dose: For oral administration only.

To ensure administration of a correct dose, body weight should be determined as accurately as possible. The recommended dose rates are: 15mg/kg bodyweight febantel, 5 mg/kg pyrantel (equivalent to 14.4 mg/kg pyrantel embonate) and 5 mg/kg praziquantel. This is equivalent to 1 tablet per 10 kg (22 lbs) bodyweight. It is important to follow the treatment recommendations as presented here. Do not deviate from the recommendations without the advice of your veterinary surgeon.

Not for use in dogs weighing less than 3 kg.

Puppies should be treated at 2 weeks of age and every 2 weeks until 12 weeks of age. Thereafter they should be treated at 3 month intervals. It is advisable to treat the bitch at the same time as the puppies. For the control of Toxocara, nursing bitches should be dosed 2 weeks after giving birth and every two weeks until weaning. For routine worm control adult dogs should be treated every 3 months.

For routine treatment a single dose is recommended. In case of suspected heavy roundworm infestation, please contact your veterinary surgeon for diagnosis and treatment recommendation.

Do not use simultaneously with piperazine compounds as piperazine may block the action of pyrantel embonate contained in this product. Other worming products may contain piperazine.

Do not use simultaneously with other deworming products without veterinary advice.

Do not use in animals with a known sensitivity to the active ingredients or to any of the excipients.

Special warnings for each target species

Fleas serve as intermediate hosts for one common type of tapeworm – Dipylidium caninum. Tapeworm infestation is certain to reoccur unless control of intermediate hosts such as fleas, mice, etc. is undertaken. Tapeworm infestation is unlikely in pups less than 6 weeks of age. Parasite resistance to any particular class of anthelmintic may develop following frequent, repeated use of an anthelmintic of that class.

i) Special precautions for use in animals

Do not exceed the stated dose, especially when treating pregnant bitches.

ii) Special precautions to be taken by the person administering the veterinary medicinal product to animals

In case of accidental ingestion, seek medical advice and show the package leaflet to the physician. In the interests of good hygiene, persons administering the tablets directly to the dog, or by adding them to the dog’s food, should wash their hands afterwards. Echinococcosis represents a hazard for humans. As echinococcosis is a notifiable disease to the World Organisation for Animal Health (OIE), specific guidelines on the treatment and follow-up, and on the safeguard of persons, need to be obtained from the relevant competent authority.

Consult a veterinary surgeon before treating pregnant animals. Teratogenic effects attributed to high doses of febantel have been reported in sheep and rats. No studies have been performed in dogs during early pregnancy. Use of the product during pregnancy should be in accordance with a benefit risk assessment by the responsible veterinarian. It is recommended that the product is not used in dogs during the first 4 weeks of pregnancy.

The product may be used in lactating bitches from two weeks after giving birth.

Do not use simultaneously with piperazine compounds. Concurrent use with other cholinergic compounds can lead to toxicity.
Withdrawal period
Not applicable

if necessary The combination of praziquantel, pyrantel embonate and febantel is well tolerated in dogs. In safety studies, a single dose of 5 times the ecommended dose or greater gave rise to occasional vomiting.

In very rare cases slight and transient digestive tract disorders such as vomiting and /or diarrhoea may occur. In individual cases these signs can be accompanied by nonspecific signs such as lethargy, anorexia or hyperactivity.

The frequency of adverse reactions is defined using the following convention:

- very common (more than 1 in 10 animals displaying adverse reaction(s) during the course of one treatment)

- common (more than 1 but less than 10 animals in 100 animals)

- uncommon (more than 1 but less than 10 animals in 1,000 animals)

- rare (more than 1 but less than 10 animals in 10,000 animals)

- very rare (less than 1 animal in 10,000 animals, including isolated reports)

Do not use this veterinary medicinal product after the expiry date which is stated on the label after EXP. The expiry date refers to the last day of that month.

Do not store above 25oC. Keep immediate packaging in outer carton. Discard any unused half tablets immediately. Do not remove tablets from immediate packaging until required for use.

Any unused veterinary medicinal product or waste materials derived from such veterinary medicinal product should be disposed of in accordance with local requirements.

The product is presented in either: Individual strips composed of aluminium foil 30 µm/30 gsm extruded polythene, containing 2, 4, 6 or 8 tablets. or Individual blisters composed of 45 µm, soft temper aluminium foil and 25 µm hard temper aluminium foil, containing 2 or 8 tablets.

The strips or blisters are packed into cartons containing either 2, 4, 6 or 8 tablets.

Not all pack sizes may be marketed.

C&H Generics Ltd

c/o Michael McEvoy and Co Seville House New Dock Street Galway Ireland

Vm 40162/4014